Johnson & Johnson says it is looking to grow within China’s pharmaceuticals industry full-speed ahead and announced plans to new acquisitions in the market.
Reports say J&J’s sales in China last year saw a 10 percent increase from 2012, and the company is now running with its success. J&J CEO Alex Gorsky told reporters that the company now wants to acquire drug and consumer health brands in China to expand current partnerships with Chinese drug makers.
Reports say J&J has placed one of its chairmen in charge of all operations in China to facilitate the company’s direction.
The company added that it is not deterred by recent criticism against Chinese government officials accused of unfairly treating foreign companies. Johnson & Johnson was fined by Chinese competition officials for “monopolistic pricing” of its contact lens operations.
Full content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Partially Dismisses Investor Suit Against Google Over Ad Practices
Mar 25, 2025 by
CPI
UK Watchdog Scrutinizes Ticketmaster’s Dynamic Pricing Amid Oasis Ticket Controversy
Mar 25, 2025 by
CPI
Democratic Senators Urge White House to Seek Congressional Approval for TikTok Deadline Extension
Mar 25, 2025 by
CPI
Spain’s Antitrust Authority Probes Generali and Sanitas Over Competition Concerns
Mar 25, 2025 by
CPI
EU Lawmakers Warn Against Weakening AI Regulations
Mar 25, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mobile Ecosystems
Mar 24, 2025 by
CPI
Mobile Ecosystems: An Intellectual Entelechy but A Necessary Model
Mar 24, 2025 by
Alba Ribera Martinez
Creating Contestability and Fairness in Mobile Ecosystems: The Contribution of the DMA
Mar 24, 2025 by
Damien Geradin & Daniel Mandrescu
Digital Ecosystems and the Not (Yet) As Efficient Competitor Principle
Mar 24, 2025 by
Thomas Hoppner & Philipp Westerhoff
Assessing the Competition Law Scrutiny of Smart Wearables and Mobile AR/VR Devices
Mar 24, 2025 by
Kayvan Hazemi-Jebelli